August 2016 Newsletter
Support the IASLC Foundation on Amazon Smile
Amazon Smile is a program that allows you to support your favorite charities each time you shop. IASLC is now enrolled in Amazon Smile, which means that you can support life-saving lung cancer research with the simple click of a mouse.
All donations to IASLC support the IASLC Foundation. The Foundation supports the IASLC's various fellowship programs, which seek to cultivate the next generation of promising lung cancer investigators. Shop through Amazon Smile by clicking the link on the IASLC Foundation page.
Regional Organizing Committee (ROC) Application for WCLC 2019 (Europe)
Applications are now being accepted for parties interested in forming a Regional Organizing Committee (ROC) for the IASLC's 20th World Conference on Lung Cancer (WCLC), which will take place in Barcelona, Spain in November 2019. The ROC will be composed of 15-20 IASLC members, and will provide regional leadership to help develop the WCLC's scientific program, social events, and overall logistical plan.
Other responsibilities of the ROC include: planning onsite workshops, arranging travel grants and awards, and assisting with press releases and marketing efforts. For a full description of the ROC's role and a link to the application, please visit our website or download application.
Academic, Career, and Funding Opportunities
As a service to our members, we post opportunities related to lung cancer and other thoracic malignancies on our website.
This now includes academic career opportunities. Click here to review post-doctoral and other career opportunities submitted to IASLC. If you have an academic career opportunity, please email it to email@example.com.
We also post opportunities when we receive information from grantors. We currently have five funding opportunities:
These opportunities are available to applicants from all countries. Click here to learn more.
Social Media Corner: Improving Your Conference Experience Through Social Media
H. Jack West, MD Swedish Cancer Institute Seattle, WA
Professional conferences have been transformed by the growing use of social media, which adds an additional layer of discussion and shared insight. Twitter is a valuable tool for sharing timely information as it emerges. Through Twitter, you can share a concise summary of key findings, and include links to broader discussions, articles, images, and key figures.
Twitter limits messages to 140 characters. However, one “workaround” of this limitation is to write a longer article using Notepad or Word, take a screenshot of your document, and then upload that photo in a tweet. Using a conference or session-specific hashtag allows people both at and outside the meeting to “share notes," offer insights, and ask questions that can be addressed during the session. The utility of Twitter has led to its ever-growing use, and many conference organizers have incorporated it as an important way to enrich the meeting experience, as well as to share information with those unable to attend.
August 2016: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The selected articles will be made available to the public for a limited time upon printing. The articles below from the August issue of the JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer
The IASLC Lung Cancer Staging Committee has embarked on revisions for the 8th edition of the TNM classification for lung cancer. Several manuscripts describing various aspects of this project have been published in this journal. This current issue provides information for coding T categories for sub-solid nodules and assessment of tumor size in part-solid tumors by Dr. Travis and colleagues.
MET exon 14 skipping mutations have been shown to be sensitive to MET inhibitors such as crizotinib. Heist and co-workers report the first clinical case of an acquired mutation in the MET kinase domain, D1228N, which was found at time of progression on crizotinib in a patient with MET exon 14 skipping.
Thymic epithelial tumors have been difficult to treat with systemic therapies, partly because they are rare, and there are few randomized trials of therapeutic regimens. Giaccone and colleagues established a cell line from a thymic carcinoma patient and, through sequencing studies, identified PI3-kinsae as a potential therapeutic target for thymic epithelial tumors. This manuscript is accompanied by an excellent editorial by Dr. Girard.
Deep-sequencing Analysis Reveals that KRAS Mutation is a Marker of Poor Prognosis in Pulmonary Sarcomatoid Carcinoma Patients
Deep-sequencing analysis reveals that KRAS mutation is a marker of poor prognosis in pulmonary sarcomatoid carcinoma patients. Lococo et al sheds light on the role of KRAS mutations in these tumors. While KRAS is not targetable at this time, the information here that KRAS mutations are a marker of poor prognosis in pulmonary sarcomatoid carcinoma patients is useful for investigators striving to develop KRAS targeting agents.
The following articles were selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with press releases that were released at the time of online publication (Published Ahead of Print).
To read more IASLC Press Releases, please visit IASLC Research Articles. These press releases are also announced via social media, so please follow IASLC on Twitter, LinkedIn, and Facebook to stay up to date on the latest scientific topics.
Nivolumab Cost-Effectiveness Improves By Selecting Non-Squamous NSCLC PD-L1+ Patients to Receive Treatment
Nivolumab (NIV), a checkpoint inhibitor approved for all squamous and non-squamous non-small cell lung cancer (NSCLC) patients in 2015, is not cost-effective when compared to treatment with docetaxel (DOC), chemotherapy medication.
Liquid Biopsies for the Identification of EGFR Mutations and for the Prediction of Lung Cancer Recurrence
Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), explored the versatility of liquid biopsies by identifying EGFR mutations using circulating tumor DNA (ctDNA) in urine and plasma and examining circulating tumor cells (CTCs) in plasma to predict the risk of lung cancer recurrence after surgical resection.
There are two ways you can access the JTO:
1. Login via the IASLC Membership Portal with your username and password. Once signed in, select “JTO Member Access” from the left hand menu and click “Journal of Thoracic Oncology.” Here, you will have access to the JTO articles free for members.
2. To get selected features on the Elsevier website like Publish-Ahead-of-Print (PAP) alerts, individual search history, or saved articles, you can also set up a custom account on the new www.jto.org site. If you have not already done so, click here to set up an account by following the steps below:
a. Click "Create Account," then complete the "Register a New Account" form and click "Register."
b. On the "Claim Online Access" page, select “I receive my subscription through a society membership”
*Please note that you will need to enter your IASLC member ID number on the first visit in order to claim your subscriber access. You will then enter a new password which will suffice for future visits to the JTO website.
Should you have any questions regarding your access to the online JTO, please contact our Membership team at: firstname.lastname@example.org.
Locating your Member ID for Registration for The IASLC 17th WCLC:
1. Begin by clicking here. Continue by entering your Username and Password. If you have forgotten your password, you can always reset it with the “Forgot Password” button on your screen. Once signed into your account, click “My Details” on the right side of your screen. You will then see your Member ID appear towards the top of your screen.
2. You will also find your Member ID in any past renewal email notices from IASLC. However, please feel free to email email@example.com and we will be happy to provide your Member ID for you right away.
COMPLIMENTARY Fellows/Residents/Students/Trainees Membership – Group Program Registration
Click Here for Program Details and Application Form or contact Director of Membership, Kristin Richeimer, or +1.720.325.2953.
Free Membership for Patients/Survivors
Update on Lung Cancer Awareness Month Strategy Project (LCAM2016)
If you would like to receive more information about the Lung Cancer Awareness Month Strategy, please contact Kristin.firstname.lastname@example.org.
Welcome New IASLC Members through July 21, 2016 (listed by name, then country):
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
February 20 - 23 2019Santa Monica, California
April 3 - 5 2019New York, New York
April 10 - 13 2019Geneva, Switzerland